Clinical Trial Update: Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) [Phase 3]

View source ↗

Summary

This update describes a completed Phase 3 extension study to assess how long the benefits of LibiGel last for Hypoactive Sexual Desire Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• LibiGel (testosterone topical gel)

Snippet

Sponsor: BioSante Pharmaceuticals | Conditions: Hypoactive Sexual Desire Disorder | Phase 3 | Status: COMPLETED